Lascufloxacin hydrochloride is a novel fluoroquinolone antibacterial agent developed by Kyorin Pharmaceuticals in Japan for the treatment of bacterial respiratory tract infections; it exhibits potent activity against a broad spectrum of pathogens, including both aerobic and anaerobic strains, and effectively inhibits both wild-type and mutant targets, demonstrating efficacy against fluoroquinolone-resistant bacterial strains.